Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ruhe Chowdhury"'
Autor:
James Monypenny, Hanna Milewicz, Fabian Flores-Borja, Gregory Weitsman, Anthony Cheung, Ruhe Chowdhury, Thomas Burgoyne, Appitha Arulappu, Katherine Lawler, Paul R. Barber, Jose M. Vicencio, Melanie Keppler, Wahyu Wulaningsih, Sean M. Davidson, Franca Fraternali, Natalie Woodman, Mark Turmaine, Cheryl Gillett, Dafne Franz, Sergio A. Quezada, Clare E. Futter, Alex Von Kriegsheim, Walter Kolch, Borivoj Vojnovic, Jeremy G. Carlton, Tony Ng
Publikováno v:
Cell Reports, Vol 24, Iss 3, Pp 630-641 (2018)
Summary: The immunosuppressive transmembrane protein PD-L1 was shown to traffic via the multivesicular body (MVB) and to be released on exosomes. A high-content siRNA screen identified the endosomal sorting complexes required for transport (ESCRT)-as
Externí odkaz:
https://doaj.org/article/271d76a1d4d644ff8f8a80c533ecdc3e
Autor:
Ippokratis Korantzis, John O'Grady, Abid Suddle, Debashis Sarker, Nigel Heaton, Gillian Al-Khadimi, Dimitrios C. Ziogas, Dionysis Papadatos-Pastos, Paul Ross, Ruhe Chowdhury, Kiruthikah Thillai, Natalie Allen
Publikováno v:
European Journal of Gastroenterology & Hepatology. 29:48-55
OBJECTIVE Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but data on its use in the elderly are inconclusive. METHODS All consecutive HCC patients who were treated in our institution with sorafenib since
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15ea9f662cae6ef5e165daf15a0d3ec9
https://doi.org/10.1097/meg.0000000000000739
https://doi.org/10.1097/meg.0000000000000739
Autor:
A. Lucey, Anca Mera, Janine Mansi, Kiruthikah Thillai, V Michalarea, M.H. Ruhe Chowdhury, S. Germanou, I. Sandri, E. Karapanagiotou
Publikováno v:
Clinical Oncology. 30:e43-e44
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99188caea456916e4877e4862748a582
https://doi.org/10.1016/j.clon.2018.02.011
https://doi.org/10.1016/j.clon.2018.02.011
Autor:
Paul Ellis, Ruhe Chowdhury
Publikováno v:
Handbook of Therapeutic Antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e0abc78ab60839f6bd0f0a0cf76d8d2
https://doi.org/10.1002/9783527682423.ch72
https://doi.org/10.1002/9783527682423.ch72
Autor:
Germanou, S., Ruhe Chowdhury, M.H., Thillai, K., Lucey, A., Michalarea, V., Mera, A., Karapanagiotou, E., Sandri, I., Mansi, J.
Publikováno v:
In Clinical Oncology June 2018 30(6):e43-e44
Autor:
Kiruthikah Thillai, Dimitrios Ziogas, Dionysios Papadatos-Pastos, Ippokratis Korantzis, Mahfuja Hussain Ruhe Chowdhury, Thubeena Manickavasagar, Abid Suddle, John O'Grady, Nigel Heaton, Paul J. Ross, Debashis Sarker
Publikováno v:
Journal of Clinical Oncology. 33:e15142-e15142
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cafb7e8a53d33df1754d620307b99553
https://doi.org/10.1200/jco.2015.33.15_suppl.e15142
https://doi.org/10.1200/jco.2015.33.15_suppl.e15142
Autor:
Dimitris Ziogas, Kiruthikah Thillai, Dionysios Papadatos-Pastos, Mahfuja Hussain Ruhe Chowdhury, Ippokratis Korantzis, Thubeena Manickavasagar, Abid Suddle, John O'Grady, Nigel Heaton, Paul J. Ross, Debashis Sarker
Publikováno v:
Journal of Clinical Oncology. 33:e15141-e15141
e15141 Background: HCC is the third commonest malignancy worldwide, with the highest incidence rates in patients over 70 years of age. Although sorafenib is used for patients with advanced HCC, the...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f4db816a45e09e800df2d1283df45a4
https://doi.org/10.1200/jco.2015.33.15_suppl.e15141
https://doi.org/10.1200/jco.2015.33.15_suppl.e15141
Autor:
Dimitrios Ziogas, Kiruthikah Thillai, Ippokratis Korantzis, MH Ruhe Chowdhury, Dionysios Papadatos-Pastos, Abid Suddle, John O'Grady, Nigel Heaton, Paul J. Ross, Debashis Sarker
Publikováno v:
Journal of Clinical Oncology. 33:435-435
435 Background: HCC is the third commonest malignancy worldwide, with the highest incidence rates in patients over 75 years of age. Although sorafenib is used for patients with advanced HCC, there are concerns about the outcomes and tolerability in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec3c5393e707bfce88df210cefe5d176
https://doi.org/10.1200/jco.2015.33.3_suppl.435
https://doi.org/10.1200/jco.2015.33.3_suppl.435